Cervical Cancer Clinical Trials (as of June 2019)

ENGOT-cx14/CEEGOG/FERTISS

Leading group: CEEGOG

Clinical Trial Study: FERTISS - FERTIility Sparing Surgery in cervical cancer patients (outside trials)  

Number of patients accrued: 224

Planned number of patients: as many as possible

Participating groups: 

AGO?, BGOG, GINECO

 

 

ENGOT-cx13/AGO/FERMATA

Leading group: AGO

Clinical Trial Study: FERMATA Trial: An international randomized double-blind clinical trial of BCD-100 plus platinum-based chemotherapy with and without Bevacizumab versus placebo plus platinum-based chemotherapy with and without Bevacizumab as first-line treatment of subjects with advanced cervical cancer

Number of patients accrued: 0

Planned number of patients: 316

Participating groups: 

A-AGO, BGOG, CEEGOG, NSGO, PGOG, TRSGO

Planned start in 3Q 2019

 

 

ENGOT-cx12/BGOG-cx12

Leading group: BGOG

Clinical Trial Study: Phase 3, randomized controlled trial of Tisotumab Vedotin vs Investigator’s choice chemotherapy in 2nd or 3rd line recurrent cervical cancer

Number of patients accrued: 0

Planned number of patients: 486

Participating groups: 

NSGO, AGO, MITO, GEICO, GINECO, TRSGO, A-AGO, CEEGOG, CTI, NCRI

Planned start in 2Q 2020

 

 

ENGOT-cx11/MITO/LACC

Leading group: MITO

Clinical Trial Study: Pembrolizumab  in combination and  maintenance after concurrent chemoradiation (CCRT) in locally advanced cervical cancer (LACC): a randomized phase III study

Number of patients accrued: 0

Planned number of patients: 786

Participating groups: 

TBA

Planned start in 4Q 2019

 

 

ENGOT-cx10/GEICO-68-C/BEATcc

Leading group: GEICO

Clinical Trial Study: A randomized phase III trial of  platinum chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus platinum chemotherapy plus Paclitaxel and Bevacizumab in metastatic (stage IVB), persistent or recurrent carcinoma of the cervix (BEATcc).

Number of patients accrued: 16

Planned number of patients: 404

Participating groups: 

GINECO, ISGO, MaNGO, MITO, NSGO

Planned start in 3Q 2018

 

 

ENGOT-cx9/GEICO/REGN

Leading group: GEICO

Clinical Trial Study: An open-label, randomized, GOG/ENGOT phase 3 trial of anti-PD1 cemiplimab versus investigator's choice chemotherapy in >2 line recurrent cervical cancer

Number of patients accrued: 191

Planned number of patients: 436

Participating groups: 

BGOG, CEEGOG, MITO, PGOG

Planned start in 1Q 2018

 

 

ENGOT-cx8/BGOG-cx8/GCT1015-05

Leading group: BGOG

Clinical Trial Study: A phase 2 open-label trial of Tisotumab Vedotin (HuMax® - TF-ADC) alone or in combination in first line recurrent or stage IVB cervical cancer

Number of patients accrued: 0

Planned number of patients: 140

Participating groups: TBA

Planned start in 2Q 2018

 

  

ENGOT-cx7/NSGO/cc1-MaRuC

Leading group: NSGO

Clinical Trial Study: A randomized double-blind placebo-controlled phase II trial of Rucaparib maintenance therapy for patienst with locally advanced cancer - MaRuC

Number of patients accrued: 0

Planned number of patients: 162

Participating groups: 

BGOG, Cancer Trials Ireland, CEEGOG, EORCT, GEICO, ISGO, MITO, NCRI, NOGGO, PGOG

Planned start in 2Q 2019

 

 

ENGOT-cx6/BGOG-cx6/GCT1015-04

Leading group: BGOG

Clinical Trial Study: A single arm, multicenter, international trial of Tisotumab Vedotin (HuMax® - TF-ADC) in previously treated, recurrent or metastatic cervical cancer 

Number of patients accrued: 93

Planned number of patients: 100

Participating groups:

TBA

Planned start in 2Q 2018

 

 

ENGOT-cx5/A-AGO/ADVANCE

Leading group: A-AGO

Clinical Trial Study: ADVANCE (ADVAxis Immunotherapy with Nivolumab to treat recurrent or metastatic CErvical Cancer), A randomized phase II study to evaluate the safety and efficacy of ADXS-602 in combination with Nivolumab

Number of patients accrued: 0

Planned number of patients: 460

Participating groups: TBA

Planned start in 2018

 

 

ENGOT-cx4/GINECO/SENTICOL

Leading group: GINECO

Clinical Trial Study: International prospective validation trial of sentinel node biopsy in cervical cancer

Number of patients accrued: 45

Planned number of patients: 950

Participating groups: 

AGO, Cancer Trials Ireland, MaNGO, NCRI, NSGO

Planned start in 2018

 

 

ENGOT-cx3/CEEGOG/ABRAX

Leading group: CEEGOG

Clinical Trial Study: Abandoning of radical hysterectomy in cervical cancer - retrospective trial

Final number of patients: 443

Participating groups: 

AGO, BGOG, MITO

Database is expected to be closed in July 2019

 

 

ENGOT-cx2/CEEGOG/SENTIX

Leading group: CEEGOG

Clinical Trial Study: SENTIX (SENTinel lymph node in cervIX cancer) - a prospective observational trial on sentinel lymph node biopsy in patients with early stage cervical cancer

Number of patients accrued: 428

Planned number of patients: 600

Participating groups:

BGOG

 

Up Coming ENGOT Meeting

Vincci Soma Hotel, Madrid, Spain

October 17-18, 2019

Don't miss out on the latest updates

Save the Date!

You May Also Like

GCA6

GCA WORKSHOPS

Watch the Webcasts 

 

Read More

background

CLINICAL TRIALS

Latest Published Research

 

Read More

patient2

FOR PATIENTS

Key Insights

 

Read More

Abstract Deadline Extended (3)

ESGO 2019 Congress

ESGO 2019 Athens Congress

 

Read More